Hepion Pharmaceuticals (FRA:336) Total Stockholders Equity : €6.92 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Hepion Pharmaceuticals Total Stockholders Equity?

Hepion Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €6.92 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Hepion Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 was €1.40. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Hepion Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.02.

Hepion Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Hepion Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hepion Pharmaceuticals Total Stockholders Equity Chart

Hepion Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

14.06

33.31

82.30

47.06

6.68

Hepion Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															34.70	24.34	15.14	6.68	6.92

Hepion Pharmaceuticals (FRA:336) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Hepion Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(6.919	-	1.559)	/	3.83829
	=	1.40

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Hepion Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.123	+	0.038)	/	6.919
	=	0.02

Hepion Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Hepion Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Hepion Pharmaceuticals (FRA:336) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (FRA:336) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

HEPA:USA

Address

399 Thornall Street, First Floor, Edison, NJ, USA, 08837

Website

https://www.hepionpharma.com

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Hepion Pharmaceuticals (FRA:336) Headlines

No Headlines